BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1521517)

  • 1. Diagnosis and endocrine testing in acromegaly.
    Chang-DeMoranville BM; Jackson IM
    Endocrinol Metab Clin North Am; 1992 Sep; 21(3):649-68. PubMed ID: 1521517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are there alternative tests for diagnosis of acromegaly?
    Popovic V
    J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current diagnostic guidelines for biochemical diagnosis of acromegaly.
    Ferone D; Resmini E; Bocca L; Giusti M; Barreca A; Minuto F
    Minerva Endocrinol; 2004 Dec; 29(4):207-23. PubMed ID: 15765030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly.
    Wass JA
    J Endocrinol; 1997 Oct; 155 Suppl 1():S17-9; discussion S21. PubMed ID: 9389991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The place of insulin-like growth factor I in the diagnosis of acromegaly].
    Dohán O; Góth M; Szabolcs I; Kovács L; Kovács Z; Szilágyi G
    Orv Hetil; 1993 Oct; 134(42):2301-3. PubMed ID: 8233444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults.
    Thissen JP; Ketelslegers JM; Maiter D
    Growth Regul; 1996 Dec; 6(4):222-9. PubMed ID: 8971551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic testing in the diagnosis and follow-up of patients with acromegaly.
    Wass JA
    J Endocrinol Invest; 2003; 26(7 Suppl):48-53. PubMed ID: 14604066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
    Wiesli P; Zwimpfer C; Zapf J; Schmid C
    Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What is the value of determining immunoreactive GHRH in acromegaly?].
    Müller B; de Marco D; Bürgi U; Mullis PE
    Schweiz Med Wochenschr; 1999 Aug; 129(33):1152-61. PubMed ID: 10483668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of reference values for endocrine tests--part V: acromegaly.
    Endert E; van Rooden M; Fliers E; Prummel MF; Wiersinga WM
    Neth J Med; 2006; 64(7):230-5. PubMed ID: 16929084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of disorders of the GH-IGF-I axis by monitoring levels of IGF-I binding protein].
    Justová V; Lacinová Z
    Sb Lek; 1998; 99(2):141-51. PubMed ID: 10536494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M; Akin F; Yaylali GF
    Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone releasing factor-test in acromegaly: comparison with other dynamic tests.
    Losa M; Schopohl J; Stalla GK; Müller OA; von Werder K
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):99-109. PubMed ID: 3931944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acromegaly.
    Dineen R; Stewart PM; Sherlock M
    QJM; 2017 Jul; 110(7):411-420. PubMed ID: 26873451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Laboratory diagnosis of growth hormone].
    Macchia V; Mariano A
    Minerva Endocrinol; 1993 Sep; 18(3 Suppl 1):36-42. PubMed ID: 7910655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.